Company announces Focal One® placements at three renowned academic institutions in March
EDAP TMS SA, the global leader in robotic energy-based therapies, today provided an update on recent Focal One® placements at select customer sites in the U.S.
During the first quarter 2022, the company sold three Focal One® machines. Notably, all three occurred at prestigious academic and integrated health network reference centers, including: New York-Presbyterian/Weill Cornell Medical Center, Beth Israel Deaconess Lahey Health, an affiliate of Harvard Medical School, and University of California Davis Medical Center in Sacramento. UC Davis represents the company’s fourth placement within the University of California Health System, following earlier placements at UC San Francisco, UC Irvine and UC San Diego.
In addition, the Company announced the sale of five ExactVu micro-ultrasound systems in the US during the first quarter.
Marc Oczachowski, EDAP's Chairman and Chief Executive Officer, said: “The success that we achieved in the U.S. during the first quarter reflects the tireless work of Ryan and the world class team that he has assembled. I am excited that we have had such a strong start to the year.”
Ryan Rhodes, CEO of EDAP U.S., said, “The results in the first quarter further validate the momentum behind focal therapy amongst leading prostate cancer centers in the U.S. We continue to build our organization to support and significantly expand the number of sites using robotic focal HIFU with Focal One® in 2022.”
EDAP plans to report full first quarter 2022 financial and operating results in mid-May.